Although there is a great body of pre-clinical evidence that RANK signaling promotes proliferation and (bone) metastatic progression of breast cancer [23, 28, 29], it still controversially discussed, whether targeted inhibition of RANK signalling by denosumab treatment will confer clinical benefit in patients with early breast cancer. This evidence concerns the gene TNFRSF11A and breast cancer.